QIAGEN N.V.

383 articles with QIAGEN N.V.

• QIAGEN Informatics Solutions Chosen to Support Genomics England’s Bold Five Million Genomes in Five Years Project

  2/4/2019

  QCI is a powerful, high quality decision support solution for rapid interpretation of hereditary diseases

• QIAGEN Reports Results for Fourth Quarter and Full-Year 2018

  2/4/2019

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2018, meeting the goal for full-year net sales and exceeding the goal for adjusted earnings per share while driving global expansion of its Sample to Insight portfolio of molecular testing solutions.

• QIAGEN N.V. to Report Fourth Quarter and Full Year 2018 Results

  1/17/2019

  QIAGEN N.V. plans as previously announced to release its report on results for the fourth quarter 2018 on Monday, February 4 at approximately 22:05 Central European Time (CET) / 16:05 Eastern Standard Time (EST).

• QIAGEN’s QuantiFERON®-TB Gold Plus Gains Approval in Canada

  1/14/2019

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Health Canada regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic test to detect latent tuberculosis (TB) infection.

• QIAGEN Unveils Plans for Next-Generation Digital PCR Systems

  1/7/2019

  Preparing for 2020 launch of novel digital PCR systems with fully integrated workflow and menu of QIAGEN assays, advantages of improved multiplexing, throughput and scalability

• QIAGEN to Develop QuantiFERON®-TB Access as a New Test for Low-Resource, High-Burden Regions in Global Fight Against TB

  1/7/2019

  Adapting the power of QuantiFERON®-TB technology to advance global TB control efforts in new partnership with Ellume

• QIAGEN Launches QIAcube Connect – Next-Generation Automation for Sample Processing in Research Labs

  1/7/2019

  Enabling labs to efficiently process increasingly complex samples with over 3,000 proven protocols, advanced digital capabilities and connectivity

• QIAGEN Acquires N-of-One, Expanding Its Clinical Bioinformatics Capabilities in Molecular Oncology Decision Support

  1/7/2019

  Enhancing QIAGEN’s industry-leading position with access to MarkerMine™ database and real-world evidence insights that provide insights for targeted therapy options

• QIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase - Dec 19, 2018

  12/19/2018

  QIAGEN N.V. announces that it will initiate the repurchase of a third tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018

• QIAGEN announces new collaboration to develop companion diagnostic to guide treatment for patients with PIK3CA-mutated advanced breast cancer

  12/6/2018

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that a clinical development program is underway with Novartis to bring to market a molecular test as a companion diagnostic to guide the use of the investigational compound BYL719 (alpelisib) in combination with fulvestrant for men and postmenopausal women living with PIK3CA mutated hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

• QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs

  11/30/2018

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients

• QIAGEN Reports Results for Third Quarter and First Nine Months of 2018

  10/29/2018

  Q3 2018 results exceed targets as QIAGEN on track to achieve 2018 goals

• QIAGEN Expands QIAGEN Clinical Insight Software to Support All Major Sequencing Platforms and Assay Types

  10/29/2018

  Adding QCI Analyze Universal to NGS bioinformatics offering, plus immuno-oncology content and additional features in analysis and interpretation

• QIAGEN Expands Next-Generation Sequencing Portfolio with Oncology and Immuno-Oncology Panels for Research Using GeneReader NGS System and Other Platforms

  10/29/2018

  Sample to Insight solutions enabling deep analysis of disease-related genomic mutations

• QIAGEN N.V. to Report Third Quarter and First Nine Months of 2018 Results

  10/15/2018

  QIAGEN N.V. plans as previously announced to release its report on results for the third quarter 2018 on Monday, October 29 shortly after 21:00 Central European Time (CET) / 16:00 Eastern Daylight Time (EDT).

• QIAGEN’s Next-Generation QIAstat-Dx System Delivers Fast, Cost-Effective Diagnosis of Gastrointestinal Syndromes

  10/15/2018

  New gastrointestinal panel includes comprehensive viral coverage and provides Sample to Insight workflows to clinics in Europe and Australia

• QIAGEN Launches Novel RNA-Seq Library Preparation Solutions for Next-Generation Sequencing

  10/11/2018

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a breakthrough technology enabling faster, simpler library preparation for RNA sequencing.

• QIAGEN and NeuMoDx Announce Strategic Partnership to Offer Next-Generation Systems for Fully Integrated Molecular Diagnostic Testing

  9/17/2018

  QIAGEN to launch two Sample to Insight systems in Europe and other markets, NeuMoDx to commercialize in the U.S. / Initial assay menu for infectious diseases and LDTs

• QIAGEN and DiaSorin Launch Automated Testing for Latent TB infection with QuantiFERON-TB Gold Plus Technology on Widely Used LIAISON Platforms

  9/17/2018

  CE-marked workflow enables efficient, high-throughput screening for tuberculosis control efforts in Europe and other markets; introduction in United States expected in 2019 and China in 2020

• QuantuMDx Group announces executive appointments

  9/11/2018

  QuantuMDx Group Ltd, the UK-based multinational molecular diagnostics company, today announced two key leadership appointments. Dr Allan Brown has been appointed Chief Operating Officer and David Matthews joins as Chief Financial Officer.